DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous STADA Arzneimittel AG: Sales and earnings key figures in the first quarter of 2015 not as significantly burdened by CIS crisis as expected - Positive trend in Central Europe, Germany as well as Asia/Pacific & MENA 07.05.2015 / 07:25 --------------------------------------------------------------------- Important items at a glance - Group sales decrease by 4 percent - adjusted -4 percent - Adjusted EBITDA declines by 19 percent - Adjusted net income decreases by 28 percent - Sales increase in Central Europe (+3 percent) - Germany (+1 percent) - Asia/Pacific & MENA (+53 percent) - Adjusted free cash flow improves to Euro 26.9 million - Outlook for 2015 confirmed STADA key figures <pre> 1-3/2015 1-3/2014 +/- Group sales Euro 486.2 million Euro 507.4 million -4% EBITDA, reported Euro 79.2 million Euro 97.7 million -19% EBITDA, adjusted Euro 92.6 million Euro 114.7 million -19% Net income, reported Euro 21.2 million Euro 35.0 million -39% Net income, adjusted Euro 37.9 million Euro 52.6 million -28% Earnings per share Euro 0.35 Euro 0.58 -40% Earnings per share, adjusted Euro 0.62 Euro 0.87 -29% </pre> Bad Vilbel, May 7, 2015 - In the first quarter of 2015, the STADA Group was still confronted with challenging framework conditions particularly in the market region CIS/ Eastern Europe. Furthermore, the Group had to report one-time special effects in connection with currency translation effects recorded in the income statement resulting from the weakness of the Russian ruble and the strong devaluation of the Ukrainian hryvnia in the total amount of Euro 11.1 million before or Euro 9.1 million after taxes. "In view of the significant challenges, particularly in the market region CIS/Eastern Europe, we expected a difficult business development for the first quarter of 2015. In the market regions Central Europe, Germany and Asia/Pacific & MENA, however, sales development was positive. Adjusted free cash flow therefore improved substantially", says Hartmut Retzlaff, Chairman of the Executive Board of STADA Arzneimittel AG. Development of sales Group sales in the first three months of 2015 recorded a decrease of 4 percent to Euro 486.2 million (1-3/2014: Euro 507.4 million). Sales of the core segment Generics decreased by 3 percent to Euro 289.8 million in the reporting period (1-3/2014: Euro 299.5 million), primarily due to the development in the market region CIS/Eastern Europe mainly in the markets of Russia and Serbia. Generics contributed 59.6 percent to Group sales (1-3/2014: 59.0 percent). Sales of the core segment Branded Products declined by 6 percent to Euro 185.1 million in the reporting period (1-3/2014: Euro 196.8 million). The primary reason for this decrease was the development in the Russian market. Branded Products contributed 38.1 percent to Group sales (1-3/2014: 38.8 percent). Development of earnings Both reported key earnings figures and adjusted key earnings figures decreased considerably in the first three months of 2015. This development was primarily due to negative currency effects from the considerable weakness of the Russian ruble and the strong devaluation of the Ukrainian hryvnia as well as an exceptionally strong comparative quarter in Ukraine, which was characterized by pull-forward effects. In addition, the fourth quarter of 2014 in Russia was marked by a high level of orders from wholesalers and pharmacies in anticipation of expected price increases, which had a curbing effect on sales in the first quarter of 2015. Reported operating profit decreased in the first quarter of 2015 by 20 percent to Euro 50.4 million (1-3/2014: Euro 63.1 million). Reported EBITDA showed a decline of 19 percent to Euro 79.2 million (1-3/2014: Euro 97.7 million). Reported net income decreased by 39 percent to Euro 21.2 million (1-3/2014: Euro 35.0 million). After adjusting the key earnings figures for influences distorting the period comparison resulting from one-time special effects, adjusted operating profit decreased by 22 percent in the reporting period to Euro 68.0 million (1-3/2014: Euro 87.6 million). Adjusted EBITDA declined by 19 percent to Euro 92.6 million (1-3/2014: Euro 114,7 million). Adjusted net income decreased by 28 percent to Euro 37.9 million (1-3/2014: Euro 52.6 million). The net debt to adjusted EBITDA ratio was at 3.6 in the reporting period on linear extrapolation of the adjusted EBITDA of the first quarter of 2015 on a full-year basis (1-3/2014: 3.1). Development of the market regions The development in the four STADA market regions was as follows: In the market region Central Europe, sales increased in the first quarter of 2015 - with varying development of the countries included - by 3 percent to Euro 235.6 million (1-3/2014: Euro 229.4 million). While the United Kingdom and Spain recorded growth in sales, sales decreased in Italy and Belgium. Sales generated in this market region contributed 48.5 percent to Group sales (1-3/2014: 45.2 percent). In the market region Germany, sales increased slightly by 1 percent to Euro 127.2 million in the reporting period (1-3/2014: Euro 125.6 million). This development also resulted regardless of the fact that export activities to the MENA region are no longer disclosed in the market region Germany due to the grouping together of activities from the MENA region and from the former market region Asia & Pacific as of January 1, 2015. Overall, the market region Germany contributed 26.1 percent to Group sales (1-3/2014: 24.8 percent). In the market region CIS/Eastern Europe, sales in the first three months of the current financial year declined by 13 percent applying the exchange rates of the previous year, which was less pronounced than expected. As a result of negative currency effects, sales in euro decreased by 32 percent to Euro 89.0 million (1-3/2014: Euro 130.0 million). Sales generated in this market region had a share of 18.3 percent in Group sales (1-3/2014: 25.6 percent). In Russia, sales decreased by 21 percent applying the exchange rates of the previous year. As a result of a clearly negative currency effect of the Russian ruble, sales declined in euro by 43 percent to Euro 44.5 million (1-3/2014: Euro 78.2 million). In Serbia, sales decreased by 18 percent applying the exchange rates of the previous year. In euro, sales recorded a decrease by 21 percent to Euro 17.0 million as a result of a negative currency effect of the Serbian dinar (1-3/2014: Euro 21.6 million). In the market region Asia/Pacific & MENA, sales in the first three months of the current financial year increased by 53 percent to Euro 34.4 million (1-3/2014: Euro 22.4 million). This development is primarily attributable to growth in Vietnam, where sales rose regardless of increased price pressure in the Vietnamese tender business. Furthermore, the increase is a result of the grouping together of the former market region Asia & Pacific and the activities of the MENA region. The sales contribution of this market region to Group sales was at 7.1 percent (1-3/2014: 4.4 percent). Development of cash flow Cash flow from operating activities amounted to Euro 46.8 million in the first quarter of 2015 (1-3/2014: Euro 35.8 million). Free cash flow was at Euro 5.6 million (1-3/2014: Euro -97.4 million). Free cash flow adjusted for payments for significant investments or acquisitions and proceeds from significant disposals amounted to Euro 26.9 million (1-3/2014: Euro 18.9 million). Development, production and procurement Research and development costs amounted to Euro 16.2 million in the first quarter of the current financial year (1-3/2014: Euro 13.9 million). Worldwide, STADA launched a total of 157 individual products in the reporting period (1-3/2014: 148 product launches). Outlook In the current financial year, the Group has been confronted with very difficult framework conditions, especially as a result of the ongoing CIS crisis. In light of this, for the outlook for 2015, the Executive Board expects to be able to achieve slight overall growth in Group sales adjusted for currency and portfolio effects. Due to the recent developments of the Russian ruble and increased risks in connection with consumer mood and the general market situation, however, it anticipates a decreased earnings contribution from Russia. Taking these developments into account and based on currency relations at the time the preliminary outlook was published, the Executive Board expects a substantial decrease in adjusted EBITDA and adjusted net income. The Executive Board expects the ratio of net debt, excluding further acquisitions, to adjusted EBITDA to be at a level of nearly 3 in 2015. STADA adjustments <pre> 1-3/2015 Net income, reported Euro 21.2 million One-time effects Burden from currency translation expenses recorded in the income Euro statement resulting from the fluctuation of the Russian ruble as +9.1 well as further significant currencies of the market region CIS/ million Eastern Europe Burden from additional scheduled depreciation and other Euro measurement effects due to purchase price allocations as well as +3.5 significant product acquisitions taking financial year 2013 as million basis Burden from effects from the measurement of derivative financial Euro instruments and the underlying transactions +2.6 million Burden from the disposal of the German logistics activities Euro +1.5 million Total one-time effects Euro 16.7 million Net income, adjusted Euro 37.9 million </pre> Additional information for analysts: STADA Arzneimittel AG / Investor Relations / StadastraÃe 2-18 / 61118 Bad Vilbel - Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de Additional information for journalists: STADA Arzneimittel AG / Media Relations / StadastraÃe 2-18 / 61118 Bad Vilbel - Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: press@stada.de Or visit us in the Internet at http://www.stada.com. --------------------------------------------------------------------- 07.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: STADA Arzneimittel AG StadastraÃe 2-18 61118 Bad Vilbel Germany Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: communications@stada.de Internet: www.stada.de ISIN: DE0007251803, DE0007251845, WKN: 725180, 725184, Indices: MDAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 353661 07.05.2015
DGAP-News: STADA Arzneimittel AG: Sales and earnings key
Top 10 Most Recent News Articles
Stardock Fences 7 Targets Messy Windows Desktops Everywhere
A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...
Continue Reading
Texas Restaurants Get a New Read on Customer Demand
Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...
Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!
Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...
Continue Reading
Fox Hill Steel Marks a Long Public-Building Road Ahead
A signed steel beam is a fine civic moment, but it is not the finish line. Burlington’s new Fox Hill Elementary School has reached its topping-off milestone, with the structural steel now in place for a 91,000-square-foot, two-story facility intended to serve roughly 325 kindergarten-through-fifth-grade students. That is tangible progress, the sort nobody can fake with...
Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises
An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...
Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP
Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...
Continue Reading
Commodity Rout Tests a Market Already Short on Nerve
Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...
Continue Reading
Pressure Injury Care Needs More Than Awareness Alone
Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...
Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care
Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...
Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion
Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...
Continue ReadingTop 5 Most Recently Viewed Articles
Petrus Resources Announces Exciting Monthly Dividend Update
Petrus Resources Monthly Dividend Declaration Petrus Resources Ltd. (TSX: PRQ) is excited to share that its Board of Directors has declared a new monthly dividend. This dividend is set at $0.01 per share and is designated for the shareholders of record. The scheduled payment date is set for December 30, and this announcement comes with important information for...
Continue Reading
Important Update for Sprinklr Investors: Know Your Rights
Key Update for Sprinklr Investors Investors who have experienced losses exceeding $100,000 in Sprinklr, Inc. should take a moment to examine their rights as shareholders. Faruqi & Faruqi, LLP, a well-regarded national securities law firm, is currently investigating possible claims against Sprinklr, which is listed on the NYSE under the ticker CXM. The firm is available to...
Continue Reading
Collaborative Innovations in Multi-Omics Data Management
DNAnexus and Panomics Unite for Biopharma Excellence In the ever-evolving landscape of biopharma, data plays a pivotal role in shaping advancements and innovations. DNAnexus, a leader in precision health data management, and Panomics, renowned for AI-powered omics data discovery, have announced a collaborative initiative aimed at revolutionizing how biopharma...
Continue Reading
WisdomTree Investors May Have Claims to Explore: Pomerantz Insights
Pomerantz Investigates Potential Investor Claims Pomerantz LLP is currently investigating claims on behalf of investors of WisdomTree, Inc. (NYSE: WT). This investigation suggests a focus on the possibility of securities fraud or other unlawful business practices that may involve the Company's officers or directors. Insights on WisdomTree's Recent Challenges Recent...
Continue Reading
Introducing ROADSAVER: A Breakthrough in Carotid Stenting
Announcing the ROADSAVER Carotid Stent System Terumo Interventional Systems (TIS) is thrilled to announce the early commercial availability of the ROADSAVER™ Carotid Stent System. This FDA-approved device is specifically designed for patients with carotid artery stenosis, aiming to reduce complications that may arise after carotid endarterectomy. With the integration of...
Continue Reading